Uncategorized

Home > Uncategorized (Page 2)

16 Jul

Posted at 15:01h in Featured Post, Uncategorized by
0 Likes

Leiden, The Netherlands and Gaithersburg, MD, USA — 17 July 2026 — Toxys and the Institute for In Vitro Sciences (IIVS) are pleased to announce an expanded strategic partnership aimed at accelerating the adoption of innovative in vitro methods for chemical safety assessment. Under a...

14 Jan

Posted at 16:35h in Featured Post, Uncategorized by
2 Likes

IIVS and the Physicians Committee for Responsible Medicine co-organized a webinar series featuring Spanish-speaking experts on ocular irritation, three-dimensional models, and dermal sensitisation. Métodos alternativos en toxicidad ocular: avances, aplicaciones y aceptación regulatoria en Latinoamérica 10 April 2025 Dra. María Laura Gutiérrez Cultivos celulares 2D y 3D en el...

22 Aug

Posted at 09:33h in Featured Post, Uncategorized by
0 Likes

Allergic contact dermatitis (ACD) is an immunologic reaction to a dermal chemical ex-posure that, once triggered in an individual, will result in an allergic response following subsequent encounters with the allergen. Air Force epidemiological consultations have in-dicated that aircraft structural maintenance workers may experience ACD...

08 Jan

Posted at 16:08h in Uncategorized by
0 Likes
Our Respiratory Toxicology team has had a productive year, staying at the forefront of the latest industry developments while also contributing new insights of our own. We've had the opportunity to attend and present at key conferences, as well as showcase the exciting progress we're making in advancing in vitro toxicology testing.

08 Jan

Posted at 16:07h in Uncategorized by
0 Likes
If you will be at EUROTOX, September 8-11, stop by BOOTH #34 to speak with IIVS President, Amanda Ulrey and meet our new Client Relationship Manager Joseph Hughes. We have some new methods available for GLP use now and several others that are currently in the technology transfer phase. We look forward to catching up with you there.

24 Sep

Posted at 21:08h in Featured Post, Uncategorized by
0 Likes
Wearable devices are in contact with the skin for extended periods. As such, the device constituents should be evaluated for their skin sensitization potential, and a Point of Departure (PoD) should be derived to conduct a proper risk assessment. Without historical in vivo data, the PoD must be derived with New Approach Methods (NAMs). To accomplish this, regression models trained on LLNA data that use data inputs from OECD-validated in vitro tests were used to derive a predicted EC3 value, the LLNA value used to classify skin sensitization potency, for three adhesive monomers (Isobornyl acrylate (IBOA), N, N- Dimethylacrylamide (NNDMA), and Acryloylmorpholine (ACMO) and one dye (Solvent Orange 60 (SO60)).

07 Nov

Posted at 16:03h in Uncategorized by
0 Likes
Pre-clinical assays, including in vitro assays, rely heavily on suppliers who provide essential products or services. In the current regulatory environment, the burden is placed on the users of these products or services to ensure that the methods employed at the suppliers' facilities meet a sufficient level of quality. Variable results for the same assay controls over time could indicate high lot-to-lot variability of the test system or of critical assay components.

20 Oct

Posted at 10:23h in Uncategorized by
0 Likes
Human precision-cut lung slices (hPCLS), considered a highly relevant ex vivo model of the lung, offer native architecture and cells of the lung tissue including respiratory parenchyma, small airways, and immune competent cells. However, the irregular availability of donor lungs has limited the accessibility of this system. As described here, thousands of hPCLS can be created from 1 lung, cryopreserved, and used “on demand” by applying slicing and cryopreservation methodology improvements.